Extended Data Fig. 1: Somatic alteration landscape in PDAC: additional insights.

a, Prevalence of BRAF alteration types in PDAC, melanoma and thyroid cancer. b, Oncoprint of somatic oncogenic alterations with tumor samples grouped by genomic subtype (as in Fig. 1a) and by primary or metastasis sample type. c, Age at diagnosis across genomic groups including all patients (left, n = 2,336) and excluding patients with pathogenic germline variants (right, n = 2,006). Nominal P values indicate statistical comparison by two-sided Wilcoxon rank sum test. Boxes represent the 25th, 50th (median) and 75th percentiles. Whiskers represent the minimum and maximum values, no further than 1.5× the interquartile range (IQR) from the respective upper and lower quartiles, with points beyond this range plotted individually. d, Gene-level alteration enrichment by genetic ancestry (n = 75 genes with sufficient sample size). e, Gene-level alteration enrichment by sex (n = 75 genes with sufficient sample size). Enrichment was calculated using a two-sided Fisher exact test with P values adjusted for multiple testing by FDR for assessment of significance for d and e.